nonpulsatile tinnitus. Other diseases of inner ear
Conditions
Interventions
Intervention 1: Group A(carbamazepine): week 1 = tab 200 mg/daily week 2 -week 12= tab 600 mg/daily (300 mg/ BD). Intervention 2: Group b( oxcarbazepine ): week 1= 300 mg/daily then week2- week12 =
Treatment - Drugs
Placebo
Group A(carbamazepine): week 1 = tab 200 mg/daily week 2 -week 12= tab 600 mg/daily (300 mg/ BD)
Group b( oxcarbazepine ): week 1= 300 mg/daily then week2- week12 = 900 mg/ daily (450 mg BID)
Group C: intervention with placebo
Sponsors
Guilan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1-tinnitus history more than 6 months; 2- The patients 21-65 years with nonpulsatile tinnitus. Excllusion crateria:1-pulsatile tinnitus 2-mineare's disease 3-vestibular neurinoma 4-otosclerosis 5-the patients use of hearing-aid 6-pregnancy 7- patients with psychologic disorders need to treatment 8-the nontulerance minimal dose of carbamazepine and oxcarbazepine or hypersensitivity to these drugs 9-recent treatment with anti convulsion drugs 10-OCP consumptions and the drugs interaction with carbamazepine but are necessary to patients 10-patients with severe heart disease(CHF,IHD) 11- appearance severe drug hypersensitivity reaction during of treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tinnitus severity. Timepoint: The beginning of treatment and ending of 8th and 12th week. Method of measurement: VAS & TSI.;Quality of Life. Timepoint: The beginning of treatment and ending of 8th and 12th week. Method of measurement: TSI. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Houshang Gerami
Guilan University of Medical Sciences
Outcome results
None listed